Literature DB >> 25099611

Use of denosumab in parathyroid carcinoma with refractory hypercalcemia.

C V Tong1, Z Hussein2, N Mohd Noor2, M Mohamad2, W F Ng2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25099611     DOI： 10.1093/qjmed/hcu166

Source DB:  PubMed          Journal:  QJM        ISSN： 1460-2393


× No keyword cloud information.
  6 in total

Review 1.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

2.  Mortality factors in recurrent parathyroid cancer: a pooled analysis.

Authors:  Wen-Hsuan Tsai; Yi-Hong Zeng; Chun-Chuan Lee; Ming-Chieh Tsai
Journal:  J Bone Miner Metab       Date:  2022-02-20       Impact factor: 2.626

Review 3.  Update on parathyroid carcinoma.

Authors:  F Cetani; E Pardi; C Marcocci
Journal:  J Endocrinol Invest       Date:  2016-03-21       Impact factor: 4.256

4.  Pitfalls of using denosumab preoperatively to treat refractory severe hypercalcaemia.

Authors:  Yulong Li; Chris Y Fan; Andrea Manni; William F Simonds
Journal:  BMJ Case Rep       Date:  2020-04-28

Review 5.  Hypercalcemia of Malignancy: An Update on Pathogenesis and Management.

Authors:  Aibek E Mirrakhimov
Journal:  N Am J Med Sci       Date:  2015-11

6.  Parathyroid Carcinoma: Analysis of Patient Characteristics and Outcomes in a Retrospective Review of Eight Cases seen in a Single Center.

Authors:  Shamira Shahar; Kim Piow Lim; Masni Mohamad
Journal:  J ASEAN Fed Endocr Soc       Date:  2019-11-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.